Bangladesh’s Beximco signs agreement for COVID-19 vaccines with SIIÂ
For priority access to COVID-19 vaccines being developed by the Indian pharmaceutical companies, Bangladesh’s Beximco Pharmaceuticals has invested in the Serum Institute of India, according to the Beximco Pharmaceuticals.
The announcement of the agreement was followed after Dhaka said that it was prepared to hold trials of vaccine candidates being developed by India as both countries are attempting to suppress the viral spread.
Once the vaccine gets regulatory approvals, the Serum Institute of India will include Bangladesh amongst the nations who will be the first to obtain an agreed quantity of the serum institutes of India’s vaccine on a top priority. The investment by Beximco will be considered as an advance for the vaccines.
Beximco didn’t provide any information regarding the size of the investment in the Serum Institute of India neither the number of vaccines the company may get.
The officials of both firms said that this landmark agreement reflects the ingrained desire for partnership between both nations and their representatives, and they can go a long way towards helping to minimize the health crisis caused by the ongoing pandemic.
The firm would be the exclusive supplier of the Serum Institute of India
‘s vaccine in Bangladesh. The company will secure added doses to be distributed to Bangladesh’s private pay market and the Bangladeshi government and the company would discuss how many doses of the vaccine it needs.About the company
The company is the largest private-sector group in Bangladesh and was established by Salman Fazlur Rahman and Ahmed Sohail Fasihur Rahman in the 1970s, the firm is an emerging generic drug player committed to providing access to affordable medicines and it is producing more than 500 products encompassing broad therapeutic categories.
Bangladesh’s Beximco signs agreement for COVID-19 vaccines with SIIÂ
Author: Sruthi S
